Inotek Pharmaceuticals Corp. (ITEK) announced Tuesday morning that its Phase 3 study of Trabodenoson failed to achieve its primary endpoint of superiority in reduction of intraocular pressure compared with placebo in patients with primary open-angle glaucoma.
from RTT - Before the Bell http://ift.tt/2j8vJAW
via IFTTT
No comments:
Post a Comment